Structured Review

Abcam anti pp2a alpha beta antibody e155
Anti Pp2a Alpha Beta Antibody E155, supplied by Abcam, used in various techniques. Bioz Stars score: 93/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti pp2a alpha beta antibody e155/product/Abcam
Average 93 stars, based on 9 article reviews
Price from $9.99 to $1999.99
anti pp2a alpha beta antibody e155 - by Bioz Stars, 2022-10
93/100 stars

Images

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Abcam anti pp2a
    CIP2A, I2PP2A, and <t>PP2A</t> in neuroblastoma cell lines. (A) Immunoblotting revealed CIP2A, I2PP2A, and PP2A expression in all four neuroblastoma cell lines studied. There were no differences in expression between the MYCN nonamplified SH-EP and the isogenic MYCN amplified WAC2 cells. (B) SK-N-AS and SH-EP neuroblastoma cells ( MYCN nonamplified) were transfected with MYCN overexpression vector and cell lysates examined for I2PP2A and PP2A. MYCN was successfully expressed in both cell lines. Expression of I2PP2A and PP2A was not affected by MYCN overexpression. (C). Neuroblastoma cell lines were treated with siRNA knockdown of I2PP2A. Whole cell lysates revealed knockdown of I2PP2A with no change in PP2A expression. (D) Neuroblastoma cell lines were treated with siRNA knockdown of CIP2A. Whole cell lysates revealed knockdown of CIP2A with no change in PP2A expression. (E) PP2A activity was measured in SK-N-AS cells following siRNA inhibition. Inhibition of I2PP2A, CIP2A, or dual inhibition led to significant increases in PP2A activity.
    Anti Pp2a, supplied by Abcam, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti pp2a/product/Abcam
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti pp2a - by Bioz Stars, 2022-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    CIP2A, I2PP2A, and PP2A in neuroblastoma cell lines. (A) Immunoblotting revealed CIP2A, I2PP2A, and PP2A expression in all four neuroblastoma cell lines studied. There were no differences in expression between the MYCN nonamplified SH-EP and the isogenic MYCN amplified WAC2 cells. (B) SK-N-AS and SH-EP neuroblastoma cells ( MYCN nonamplified) were transfected with MYCN overexpression vector and cell lysates examined for I2PP2A and PP2A. MYCN was successfully expressed in both cell lines. Expression of I2PP2A and PP2A was not affected by MYCN overexpression. (C). Neuroblastoma cell lines were treated with siRNA knockdown of I2PP2A. Whole cell lysates revealed knockdown of I2PP2A with no change in PP2A expression. (D) Neuroblastoma cell lines were treated with siRNA knockdown of CIP2A. Whole cell lysates revealed knockdown of CIP2A with no change in PP2A expression. (E) PP2A activity was measured in SK-N-AS cells following siRNA inhibition. Inhibition of I2PP2A, CIP2A, or dual inhibition led to significant increases in PP2A activity.

    Journal: Translational Oncology

    Article Title: Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth

    doi: 10.1016/j.tranon.2018.09.011

    Figure Lengend Snippet: CIP2A, I2PP2A, and PP2A in neuroblastoma cell lines. (A) Immunoblotting revealed CIP2A, I2PP2A, and PP2A expression in all four neuroblastoma cell lines studied. There were no differences in expression between the MYCN nonamplified SH-EP and the isogenic MYCN amplified WAC2 cells. (B) SK-N-AS and SH-EP neuroblastoma cells ( MYCN nonamplified) were transfected with MYCN overexpression vector and cell lysates examined for I2PP2A and PP2A. MYCN was successfully expressed in both cell lines. Expression of I2PP2A and PP2A was not affected by MYCN overexpression. (C). Neuroblastoma cell lines were treated with siRNA knockdown of I2PP2A. Whole cell lysates revealed knockdown of I2PP2A with no change in PP2A expression. (D) Neuroblastoma cell lines were treated with siRNA knockdown of CIP2A. Whole cell lysates revealed knockdown of CIP2A with no change in PP2A expression. (E) PP2A activity was measured in SK-N-AS cells following siRNA inhibition. Inhibition of I2PP2A, CIP2A, or dual inhibition led to significant increases in PP2A activity.

    Article Snippet: Primary antibodies used for Western blotting included the following: anti-I2PP2A (H-120) (sc-25564) from Santa Cruz Biotechnology (Santa Cruz, CA), anti-PP2A (ab32104) and anti-CIP2A (ab99518) from Abcam (Cambridge, MA), anti–total AKT (9272), anti–phospho-AKT (S473; 9271), anti-MYCN (9405), p44/42 MAP Kinase [ERK1/2 (9102)], anti–phospho-p44/42 MAPK [phospho-ERK, T202/T204, (4377)] from Cell Signaling Technology (Danvers, MA), and anti–β-actin from Sigma (A1978, Sigma Aldrich, St. Louis, MO).

    Techniques: Expressing, Amplification, Transfection, Over Expression, Plasmid Preparation, Activity Assay, Inhibition

    FTY720 treatment increased protein phosphatase 2A activity. ( A ) H E staining confirmed histology consistent with medulloblastoma in PDXs ( top panels ). Immunohistochemistry was performed to demonstrate I2PP2A, CIP2A and PP2A expression in formalin-fixed, paraffin-embedded human medulloblastoma PDXs. IgG negative controls reacted appropriately ( second row panels, lower left insets) . ( B ) Immunoblotting confirmed I2PP2A, CIP2A, and PP2A expression in whole cell lysates from these 3 medulloblastoma PDXs. ( C ) PP2A activity was measured in all 3 medulloblastoma PDXs. Treatment with FTY720 (5 µM) for 4 hours resulted in a significant increase in PP2A activity in all three PDX’s tested (*p ≤ 0.05). Experiments were repeated at least in triplicate and reported as mean ± SEM. ( D ) Protein levels of CIP2A and I2PP2A (SET) were measured following FTY720 treatment. CIP2A was diminished in the D341 and D384 MB PDXs ( top left and middle panels ), but not in the D425 MB PDX ( top right panel ). I2PP2A levels were not altered ( middle panels ).

    Journal: Scientific Reports

    Article Title: FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

    doi: 10.1038/s41598-018-25263-5

    Figure Lengend Snippet: FTY720 treatment increased protein phosphatase 2A activity. ( A ) H E staining confirmed histology consistent with medulloblastoma in PDXs ( top panels ). Immunohistochemistry was performed to demonstrate I2PP2A, CIP2A and PP2A expression in formalin-fixed, paraffin-embedded human medulloblastoma PDXs. IgG negative controls reacted appropriately ( second row panels, lower left insets) . ( B ) Immunoblotting confirmed I2PP2A, CIP2A, and PP2A expression in whole cell lysates from these 3 medulloblastoma PDXs. ( C ) PP2A activity was measured in all 3 medulloblastoma PDXs. Treatment with FTY720 (5 µM) for 4 hours resulted in a significant increase in PP2A activity in all three PDX’s tested (*p ≤ 0.05). Experiments were repeated at least in triplicate and reported as mean ± SEM. ( D ) Protein levels of CIP2A and I2PP2A (SET) were measured following FTY720 treatment. CIP2A was diminished in the D341 and D384 MB PDXs ( top left and middle panels ), but not in the D425 MB PDX ( top right panel ). I2PP2A levels were not altered ( middle panels ).

    Article Snippet: The primary antibodies anti-I2PP2A/SET (rabbit polyclonal, 1:400, sc-25564, Santa Cruz), anti-CIP2A (rabbit polyclonal, 1:200, ab99518, Abcam), and anti-PP2A (rabbit monoclonal, 1:200, ab32104, Abcam) were added and incubated for 1 hour in a humidity chamber at room temperature.

    Techniques: Activity Assay, Staining, Immunohistochemistry, Expressing, Formalin-fixed Paraffin-Embedded

    FTY720 treatment increased protein phosphatase 2A activity. ( A ) H E staining confirmed histology consistent with medulloblastoma in PDXs ( top panels ). Immunohistochemistry was performed to demonstrate I2PP2A, CIP2A and PP2A expression in formalin-fixed, paraffin-embedded human medulloblastoma PDXs. IgG negative controls reacted appropriately ( second row panels, lower left insets) . ( B ) Immunoblotting confirmed I2PP2A, CIP2A, and PP2A expression in whole cell lysates from these 3 medulloblastoma PDXs. ( C ) PP2A activity was measured in all 3 medulloblastoma PDXs. Treatment with FTY720 (5 µM) for 4 hours resulted in a significant increase in PP2A activity in all three PDX’s tested (*p ≤ 0.05). Experiments were repeated at least in triplicate and reported as mean ± SEM. ( D ) Protein levels of CIP2A and I2PP2A (SET) were measured following FTY720 treatment. CIP2A was diminished in the D341 and D384 MB PDXs ( top left and middle panels ), but not in the D425 MB PDX ( top right panel ). I2PP2A levels were not altered ( middle panels ).

    Journal: Scientific Reports

    Article Title: FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

    doi: 10.1038/s41598-018-25263-5

    Figure Lengend Snippet: FTY720 treatment increased protein phosphatase 2A activity. ( A ) H E staining confirmed histology consistent with medulloblastoma in PDXs ( top panels ). Immunohistochemistry was performed to demonstrate I2PP2A, CIP2A and PP2A expression in formalin-fixed, paraffin-embedded human medulloblastoma PDXs. IgG negative controls reacted appropriately ( second row panels, lower left insets) . ( B ) Immunoblotting confirmed I2PP2A, CIP2A, and PP2A expression in whole cell lysates from these 3 medulloblastoma PDXs. ( C ) PP2A activity was measured in all 3 medulloblastoma PDXs. Treatment with FTY720 (5 µM) for 4 hours resulted in a significant increase in PP2A activity in all three PDX’s tested (*p ≤ 0.05). Experiments were repeated at least in triplicate and reported as mean ± SEM. ( D ) Protein levels of CIP2A and I2PP2A (SET) were measured following FTY720 treatment. CIP2A was diminished in the D341 and D384 MB PDXs ( top left and middle panels ), but not in the D425 MB PDX ( top right panel ). I2PP2A levels were not altered ( middle panels ).

    Article Snippet: The primary antibodies anti-I2PP2A/SET (rabbit polyclonal, 1:400, sc-25564, Santa Cruz), anti-CIP2A (rabbit polyclonal, 1:200, ab99518, Abcam), and anti-PP2A (rabbit monoclonal, 1:200, ab32104, Abcam) were added and incubated for 1 hour in a humidity chamber at room temperature.

    Techniques: Activity Assay, Staining, Immunohistochemistry, Expressing, Formalin-fixed Paraffin-Embedded